These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 20703031)

  • 21. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?
    Uludag G; Hassan M; Matsumiya W; Pham BH; Chea S; Trong Tuong Than N; Doan HL; Akhavanrezayat A; Halim MS; Do DV; Nguyen QD
    Expert Opin Biol Ther; 2022 Oct; 22(10):1275-1291. PubMed ID: 35818801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
    Ip MS; Domalpally A; Sun JK; Ehrlich JS
    Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-vascular endothelial growth factor agents for diabetic maculopathy.
    Salam A; DaCosta J; Sivaprasad S
    Br J Ophthalmol; 2010 Jul; 94(7):821-6. PubMed ID: 19556214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-VEGF therapy in proliferative diabetic retinopathy.
    Abdallah W; Fawzi AA
    Int Ophthalmol Clin; 2009; 49(2):95-107. PubMed ID: 19349790
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues.
    Stewart MW
    Curr Diabetes Rev; 2012 Jul; 8(4):237-46. PubMed ID: 22515701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Vascular Endothelial Growth Factor Injections: The New Standard of Care in Proliferative Diabetic Retinopathy?
    Li X; Zarbin MA; Bhagat N
    Dev Ophthalmol; 2017; 60():131-142. PubMed ID: 28427072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 29. Ranibizumab for diabetic retinopathy.
    Rodriguez-Fontal M; Alfaro V; Kerrison JB; Jablon EP
    Curr Diabetes Rev; 2009 Feb; 5(1):47-51. PubMed ID: 19199898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-VEGF for the management of diabetic macular edema.
    Stefanini FR; Badaró E; Falabella P; Koss M; Farah ME; Maia M
    J Immunol Res; 2014; 2014():632307. PubMed ID: 24741610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and investigational drugs for the treatment of diabetic retinopathy.
    Tolentino MS; Tolentino AJ; Tolentino MJ
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1011-22. PubMed ID: 27367620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].
    Kakkassery V; Winterhalter S; Joussen AM
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):701-11. PubMed ID: 20845250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anti-VEGF therapy to treat diabetic macular edema].
    Takamura Y
    Nippon Ganka Gakkai Zasshi; 2014 Sep; 118(9):747-9. PubMed ID: 25318182
    [No Abstract]   [Full Text] [Related]  

  • 35. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetic Macular Edema: Options for Adjunct Therapy.
    Calvo P; Abadia B; Ferreras A; Ruiz-Moreno O; Verdes G; Pablo LE
    Drugs; 2015 Sep; 75(13):1461-9. PubMed ID: 26242766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on nonsurgical therapy for diabetic macular edema.
    Witkin AJ; Brown GC
    Curr Opin Ophthalmol; 2011 May; 22(3):185-9. PubMed ID: 21427573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema.
    Moshfeghi DM; Kaiser PK; Michels S; Midena E; Kitchens JW; Prenner JL; Regillo CD; Reichel E
    Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6 Suppl):S4-S14. PubMed ID: 27348433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial growth factor and diabetic macular edema.
    Lally DR; Shah CP; Heier JS
    Surv Ophthalmol; 2016; 61(6):759-768. PubMed ID: 27045225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.